1. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK JAK/STAT Signaling
  2. Antibody-Drug Conjugates (ADCs) EGFR
  3. Disitamab vedotin

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity.

For research use only. We do not sell to patients.

CAS No. : 2136633-23-1

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Top Publications Citing Use of Products

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Disitamab vedotin (DV, 0.25 μg/mL) reduced the overall cell number of HER2-positive JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900.  [Abstract]

    Unlike the parental cells, which were sensitive to XMT-1522 and Disitamab vedotin (DV, 0.0001, 0.0006, 0.003, 0.016, 0.08, 0.4, 1, 2, and 10 μg/mL; 5 days), both D1 and D2 daughter cells that emerged from the DTP-PGCC were resistant to these drugs. D1, daughter-1 cells (one prior ADC treatment); D2, daughter-2 cells (two prior ADC treatments). ∗∗, p < 0.01; ∗∗∗, p < 0.001.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    Disitamab vedotin (DV, 50 μg/mL, 15 or 30 min) increased T-DM1 internalization into JIMT-1 breast cancer cells.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In JIMT-1 xenografts, the combination of Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) plus T-DM1, as well as DV plus T-DXd, inhibited tumor growth more effectively than the corresponding single treatments.

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284.  [Abstract]

    In macroscopic JIMT-1 xenografts, tumors that relapsed after T-DM1 treatment and subsequently responded to Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) but later progressed had lost HER2 expression. A: PBS; B: relapsed after T-DM1, progressed on T-DM1; C: relapsed after T-DM1, progressed on DV; D: relapsed after T-DM1, progressed on T-DXd.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity[1].

    IC50 & Target[1]

    HER2

     

    In Vitro

    The antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    149000 (average)

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    [Disitamab vedotin]

    Shipping

    Shipping with dry ice.

    Storage

    -80°C, protect from light

    Purity & Documentation

    Purity: 98.90%

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Disitamab vedotin
    Cat. No.:
    HY-P9985
    Quantity:
    MCE Japan Authorized Agent: